Payment overview · 2025
General Payments
$349.29
17 reported records · 10 companies
Healthcare provider profile · identity verified
Smita V Patel, MD
Allopathic & Osteopathic Physicians|Family Medicine · GRANGER, IN · NPI 1518180512
Verified facts
What the public records show
CMS Open Payments records show Smita V Patel, MD received $349.29 in general payments during 2025 across 17 reported records.
AstraZeneca Pharmaceuticals LP accounted for 14.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $50.47 | 14.4% | 3 | 2025 |
| UROGEN PHARMA, INC. | Unresolved — no canonical attribution shown | $46.69 | 13.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $45.22 | 12.9% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $44.13 | 12.6% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $37.00 | 10.6% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $32.87 | 9.4% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $29.64 | 8.5% | 1 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $27.26 | 7.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $20.15 | 5.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.86 | 4.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $330.44 | 16 |
| Education | $18.85 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $53.87 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $50.47 | 3 | 2025 |
Source payment records
|
|||||
| JELMYTO Normalized: jelmyto |
Drug | UROGEN PHARMA, INC. | $46.69 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $45.22 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $44.13 | 3 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $29.64 | 1 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $27.26 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $20.15 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.00 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.00 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.86 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
48 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
62 | 62 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
82 | 69 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 554 | 154 |
| Levothyroxine Sodium | Levothyroxine Sodium | 449 | 110 |
| Amlodipine Besylate | Amlodipine Besylate | 334 | 99 |
| Losartan Potassium | Losartan Potassium | 278 | 75 |
| Hydrochlorothiazide | Hydrochlorothiazide | 238 | 65 |
| Omeprazole | Omeprazole | 221 | 73 |
| Lisinopril | Lisinopril | 213 | 62 |
| Simvastatin | Simvastatin | 191 | 54 |
| Metformin Hcl Er | Metformin Hcl | 152 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 146 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 146 | 43 |
| Montelukast Sodium | Montelukast Sodium | 140 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 126 | 39 |
| Gabapentin | Gabapentin | 124 | 44 |
| Metformin Hcl | Metformin Hcl | 119 | 38 |
| Alendronate Sodium | Alendronate Sodium | 115 | 50 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 106 | 22 |
| Sertraline Hcl | Sertraline Hcl | 101 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 100 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 95 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 94 | 48 |
| Glipizide Er | Glipizide | 93 | 25 |
| Furosemide | Furosemide | 86 | 39 |
| Atenolol | Atenolol | 85 | 25 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 82 | 69 |
| Fluoxetine Hcl | Fluoxetine Hcl | 79 | 22 |
| Allopurinol | Allopurinol | 75 | 20 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 71 | 30 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 69 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 69 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 68 | 24 |
| Potassium Chloride | Potassium Chloride | 68 | 29 |
| Alprazolam | Alprazolam | 66 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 65 | 31 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 62 | 62 |
| Buspirone Hcl | Buspirone Hcl | 61 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 61 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 60 | 20 |
| Valsartan | Valsartan | 56 | 16 |
| Ozempic | Semaglutide | 54 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 53 | 16 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 52 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 50 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 49 | 14 |
| Farxiga | Dapagliflozin Propanediol | 48 | 12 |
| Tramadol Hcl | Tramadol Hcl | 48 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 48 | 11 |
| Bupropion Xl | Bupropion Hcl | 47 | 13 |
| Glimepiride | Glimepiride | 47 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 42 | 36 |
| Glipizide | Glipizide | 42 | 12 |
| Mounjaro | Tirzepatide | 42 | suppressed |
| Eliquis | Apixaban | 41 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 40 | 14 |
| Meloxicam | Meloxicam | 40 | 15 |
| Synthroid | Levothyroxine Sodium | 40 | suppressed |
| Januvia | Sitagliptin Phosphate | 38 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 38 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 36 | 12 |
| Prednisone | Prednisone | 34 | 27 |
| Donepezil Hcl | Donepezil Hcl | 31 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 19 |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 30 | 30 |
| Diclofenac Sodium | Diclofenac Sodium | 30 | 15 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | 12 |
| Spironolactone | Spironolactone | 30 | 12 |
| Naproxen | Naproxen | 28 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Nystatin | Nystatin | 27 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 27 | 14 |
| Trazodone Hcl | Trazodone Hcl | 27 | suppressed |
| Carvedilol | Carvedilol | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Klor-Con M20 | Potassium Chloride | 25 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 25 | suppressed |
| Clonazepam | Clonazepam | 24 | 13 |
| Methocarbamol | Methocarbamol | 24 | 17 |
| Spiriva Handihaler | Tiotropium Bromide | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 23 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Ezetimibe | Ezetimibe | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Famotidine | Famotidine | 21 | 11 |
| Pregabalin | Pregabalin | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 15 |
| Azithromycin | Azithromycin | 15 | 12 |
| Celecoxib | Celecoxib | 15 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Verapamil Sr | Verapamil Hcl | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Jardiance | Empagliflozin | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $349.29 · 17 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Cologuard Collection Kit, INSPIRE, JARDIANCE, JELMYTO, MOUNJARO, TRELEGY ELLIPTA, VRAYLAR, Wegovy, ZEPBOUND, t:slim X2 Insulin Pump with Control-IQ | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error